DarshanTalks Podcast

Send us Fan Mail

What happens when an artificial intelligence chatbot generates a fake medical license number and starts giving psychiatric advice?

In this episode of the KF Deep Dive, host Darshan welcomes healthcare regulatory expert and Fox Rothschild Chief Privacy Officer, Elizabeth Litten, to untangle a wild new frontier in legal tech. We break down the historic lawsuit filed by Pennsylvania Governor Josh Shapiro against Character.AI after a companion bot unlawfully held itself out as a licensed physician.

Darshan and Elizabeth pull back the curtain on the critical compliance flaws of generative AI in healthcare. From the "overwarning" dilemma in Electronic Medical Record (EMR) systems to the dangerous lack of human oversight and clinical judgment, this conversation highlights why letting AI act as a "black box" diagnostic tool is a massive liability risk.

Tune in as they discuss:

• The Character.AI Lawsuit: Why the state of Pennsylvania is cracking down on AI bots posing as licensed mental health professionals.
• The "Level 1" Error Problem: How software developers shift malpractice liability onto clinicians by forcing endless, low-level warning click-throughs.
• Consent & The Ambient AI Trap: The hidden dangers of data-scraping, the illegality of selling Protected Health Information (PHI) under HIPAA, and why doctors must get explicit patient consent before using AI note-taking tools.
• AI Governance Guidelines: Elizabeth’s top 3 compliance strategies for companies looking to safely deploy AI characters and automated tools without facing massive legal repercussions.

Whether you are a healthcare professional, a software developer, or just fascinated by the intersection of law and cutting-edge technology, this episode is a must-listen guide to navigating the untamed wild west of AI.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 NOT LEGAL ADVICE 

For decades, cannabis research in the U.S. was stifled by Schedule I restrictions, requiring high-security vaults, mountains of paperwork, and extremely limited supply chains. With Executive Order 14370, the landscape has shifted. Marijuana is moving to Schedule III, and the rules of the game have officially changed.

In this episode of KLF Deep Dive, attorney-pharmacist Darshan Kulkarni breaks down the practical impact of this reclassification for clinical trial sponsors. We move beyond the headlines to discuss the "pharmacy-style" compliance now required and the hidden pitfalls of using non-pharmacist staff at trial sites.

Key Topics Covered:

• The Security Shift: Why you can ditch the steel vaults, but why your new "pharmacy" status brings a different set of DEA headaches.
• Supply Chain Normalization: Moving away from the "one-plant" monopoly toward a traditional pharma infrastructure.
• The Real-World Evidence (RWE) Invitation: How the FDA is encouraging the use of patient records and "real-world stories" to prove efficacy.
• The Compliance Trap: Why vetting your trial sites’ staffing—specifically the use of CRNAs vs. Pharmacists—is now a top-tier regulatory risk.
• Targeting Federal Grants: Why studies focusing on veterans and the elderly are currently "first in line" for federal support.

The Bottom Line: The federal government has moved from stopping research to starting it. But as a sponsor, your site list just got bigger—and so did your responsibility to ensure they aren't just pretending to be compliant.

Support the show: www.kulkarnilawfirm.com

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Is your career protected from your company’s mistakes? For decades, a Federal Consent Decree was a corporate headache. Today, it’s a personal professional death sentence. In this episode, Darshan Kulkarni breaks down the seismic shift in federal enforcement: why agencies are now naming CEOs, CMOs, and Heads of Clinical operations by name in injunctions. We explore the "Delegation Trap," the rise of the Office of Data Reliability, and the KLF Playbook for ensuring your name never appears on a federal blackball list. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 In this episode of the KLF Deep Dive, Darshan Kulkarni deconstructs a persistent and dangerous myth circulating in life sciences and investment circles: the Private Membership Association (PMA). While often marketed as a "contract-based loophole" to evade FDA oversight and civil liability, the reality in federal court is starkly different. Darshan examines the constitutional limits of "freedom of association" and analyzes key case law—including Little v. Q Lasers—to demonstrate why PMAs are viewed by judges as red flags rather than legal shields. If you are advising clients on regulatory shortcuts, this is a must-listen briefing on maintaining professional integrity and statutory compliance. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees are tied to enrollment or revenue, you aren't just a vendor—you’re a legal liability. We break down the MSO structures that are failing, the "Red Zones" in state law, and how KLF re-architects your contracts to make you the safest, most scalable partner in the life sciences industry. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 In this tactical masterclass, Darshan Kulkarni breaks down the critical legal architecture required to protect clinical trial sites during rapid expansion. As PIs and Sub-Investigators move between organizations, the risk of losing proprietary data and patient continuity skyrockets. Learn the specific clauses—from non-solicitation to transition requirements—that ensure your site retains its value and your sponsors remain confident. Don't let your most valuable assets walk out the door; learn how to lock down your contracts today. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven science." If you are a patient, a provider, or a legal professional in the life sciences space, you need to understand the four pillars of FDA approval—and why some of the most popular drugs on the market today are legally allowed to skip the hardest parts 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Stop playing compliance theater. In this episode, Darshan Kulkarni pulls back the curtain on a dangerous trend in the life sciences: the over-reliance on contract sales forces without the legal control to back them up. Many companies believe they’ve "solved" the incentive pay problem, only to realize the OIG hasn't changed its mind since 1998.

We break down why the "Pikachu face" won't save you when the government comes knocking, the myth of the "basically an employee" legal status, and why your business model might be a walking Anti-Kickback violation. If you’re paying for results but can’t control the behavior, you aren’t scaling—you’re gambling.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 Is AI the savior of clinical research costs, or a ticking time bomb for data integrity? In this episode, Darshan Kulkarni dives into the murky waters of AI-driven sponsor protocols. We explore how AI is being used to mask—and unmask—data falsification, and what life science sponsors must do to ensure compliance before the regulators knock. If you’re using AI to "make life easier," you might be making your legal defense much harder. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

"The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting toward a compliance cliff. In this episode, Darshan Kulkarni—pharmacist and FDA regulatory lawyer—strips away the marketing hype to reveal the "messy reality" of AI in regulated environments.

We dive deep into the three pillars of risk that can sink a biotech firm:

• Data Integrity: Why AI scales bad data faster than you can fix it.
• The Ownership Crisis: Why current collaboration agreements aren't ready for probabilistic inventorship.
• The Accountability Gap: Who does the DOJ point to when the algorithm makes a $500M mistake?

If you are an executive or general counsel in the life sciences, this is the briefing you need to hear before your next M&A due diligence or patent filing.

Support the show

www.kulkarnilawfirm.com